These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15333967)

  • 21. Rosuvastatin and atorvastatin preserve renal function in HIV-1-infected patients with chronic kidney disease and hyperlipidaemia.
    Calza L; Colangeli V; Borderi M; Manfredi R; Marconi L; Bon I; Re MC; Viale P
    HIV Clin Trials; 2018 Jun; 19(3):120-128. PubMed ID: 29770749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
    Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
    Kimura Y; Hyogo H; Yamagishi S; Takeuchi M; Ishitobi T; Nabeshima Y; Arihiro K; Chayama K
    J Gastroenterol; 2010 Jul; 45(7):750-7. PubMed ID: 20112031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
    Lampl Y; Lorberboym M; Gilad R; Vysberg I; Tikozky A; Sadeh M; Boaz M
    Clin Neuropharmacol; 2010 May; 33(3):129-34. PubMed ID: 20502132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
    Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
    Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
    Takebayashi K; Matsumoto S; Wakabayashi S; Inukai Y; Matsutomo R; Aso Y; Inukai T
    Metabolism; 2005 Sep; 54(9):1225-9. PubMed ID: 16125534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes.
    van Etten RW; de Koning EJ; Honing ML; Stroes ES; Gaillard CA; Rabelink TJ
    Arterioscler Thromb Vasc Biol; 2002 May; 22(5):799-804. PubMed ID: 12006393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
    Indian Heart J; 2001; 53(2):237. PubMed ID: 11428488
    [No Abstract]   [Full Text] [Related]  

  • 31. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Samy W; Hassanian MA
    Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
    Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Gerasimidis T; Liapis CD
    J Vasc Surg; 2010 Jan; 51(1):114-21. PubMed ID: 19837545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
    Nordøy A; Hansen JB; Brox J; Svensson B
    Nutr Metab Cardiovasc Dis; 2001 Feb; 11(1):7-16. PubMed ID: 11383326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH).
    Hussein O; Grosovski M; Schlesinger S; Szvalb S; Assy N
    Dig Dis Sci; 2007 Oct; 52(10):2512-9. PubMed ID: 17404856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.
    Insull W; Kafonek S; Goldner D; Zieve F
    Am J Cardiol; 2001 Mar; 87(5):554-9. PubMed ID: 11230838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of low and high doses of atorvastatin on arterial compliance.
    Karter Y; Curgunlu A; Ertürk N; Vehid S; Mihmanli I; Ayan F
    Jpn Heart J; 2003 Nov; 44(6):953-61. PubMed ID: 14711190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
    Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
    Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
    Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.